Atlas Trials

Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer

Clinical trial NCT04308174 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04308174
Sponsor
Asan Medical Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Biliary Tract NeoplasmsGallbladder CancerCholangiocarcinoma
Start date
2020-05-20
Primary completion
2023-06-30
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.